Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Epigenetic Regulation01:37

Epigenetic Regulation

3.6K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
3.6K
Epigenetic Regulation01:46

Epigenetic Regulation

33.3K
Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
33.3K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

7.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.6K
Clinical Applications of Epidermal Stem Cells01:19

Clinical Applications of Epidermal Stem Cells

3.1K
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
3.1K
Somatic to iPS Cell Reprogramming01:29

Somatic to iPS Cell Reprogramming

2.5K
Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012...
2.5K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Bone marrow immunosuppressive states associate with survival after guadecitabine and atezolizumab therapy in HMA-R/R MDS.

Blood neoplasia·2026
Same author

Structure-guided design of 7-azaindole DNMT1 inhibitors active against hypomethylating agent-resistant acute myeloid leukemia.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Reduced Maintenance DNA Methylation Thresholds Enable Sensitive Reporter Assays for UHRF1 and DNMT1 Inhibition.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

Cell-free DNA fragmentomes for noninvasive detection of liver cirrhosis and other diseases.

Science translational medicine·2026
Same author

Pembrolizumab and epigenetic modification with azacitidine reshapes the tumor microenvironment of platinum-resistant epithelial ovarian cancer: a phase 2 non-randomized clinical trial.

Communications medicine·2026
Same author

Importance of De Novo Gene Evolution to Emerging Viral Threats: The ORF10 Strain-Restricted Orphan Gene of SARS-CoV-2 Promotes Pathogenesis.

Molecular biology and evolution·2025

Video Experimental Relacionado

Updated: Dec 23, 2025

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells
11:42

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

9.8K

Terapia epigenética para el sarcoma epitelial

Scott B Rothbart1, Stephen B Baylin2

  • 1Center for Epigenetics, Van Andel Institute, Grand Rapids, MI 49503, USA.

Cell
|April 18, 2020
PubMed
Resumen

Tazemetostat, una terapia epigenética, está aprobado por la FDA para los tumores sólidos. Inhibe EZH2, mostrando una promesa para los cánceres con mutaciones SWI / SNF, como los sarcomas epitelioides.

Más Videos Relacionados

LINE-1 Methylation Analysis in Mesenchymal Stem Cells Treated with Osteosarcoma-Derived Extracellular Vesicles
12:18

LINE-1 Methylation Analysis in Mesenchymal Stem Cells Treated with Osteosarcoma-Derived Extracellular Vesicles

Published on: February 1, 2020

6.1K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.7K

Videos de Experimentos Relacionados

Last Updated: Dec 23, 2025

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells
11:42

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

9.8K
LINE-1 Methylation Analysis in Mesenchymal Stem Cells Treated with Osteosarcoma-Derived Extracellular Vesicles
12:18

LINE-1 Methylation Analysis in Mesenchymal Stem Cells Treated with Osteosarcoma-Derived Extracellular Vesicles

Published on: February 1, 2020

6.1K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.7K

Área de la Ciencia:

  • En el campo de la oncología
  • La epigenética
  • Biología molecular

Sus antecedentes:

  • Tazemetostat representa una nueva terapia epigenética aprobada por la FDA para los tumores sólidos.
  • Funciona como un inhibidor de la lisina metiltransferasa, dirigido específicamente a EZH2.
  • EZH2 es un componente clave del Complejo Represor Polycomb 2 (PRC2), involucrado en el silenciamiento de la transcripción.

Objetivo del estudio:

  • Para resaltar la importancia de Tazemetostat como una terapia epigenética pionera.
  • Para aclarar el mecanismo de acción de Tazemetostat dirigido a EZH2.
  • Identificar los tipos de tumores sensibles a la inhibición de EZH2, en particular aquellos con mutaciones de SWI/SNF.

Principales métodos:

  • Revisión de los datos de los ensayos clínicos y de la información de aprobación de Tazemetostat por parte de la FDA.
  • Análisis bioquímico de EZH2 y su papel en el complejo PRC2.
  • Análisis genético de las mutaciones complejas de la cromatina SWI/SNF en varios tumores.

Principales resultados:

  • Tazemetostat es la primera terapia epigenética aprobada por la FDA para un tumor sólido.
  • El fármaco inhibe efectivamente la actividad de EZH2.
  • Los tumores que albergan mutaciones en las subunidades del complejo SWI/SNF demuestran sensibilidad a la inhibición de EZH2.

Conclusiones:

  • Tazemetostat ofrece una nueva vía terapéutica para los tumores sólidos, particularmente aquellos impulsados por la desregulación epigenética.
  • La eficacia del fármaco está relacionada con su capacidad para inhibir la EZH2.
  • Los sarcomas epitelioides y otros cánceres mutados por SWI/ SNF son candidatos potenciales para la terapia dirigida a EZH2.